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Abstract
Inﬂuenza vaccine provides protection against infection with matched strains, and this protection correlates with serum antibody titres.
In addition to antibodies, inﬂuenza-speciﬁc CD8+ T-lymphocyte responses are important in decreasing disease severity and facilitating
viral clearance. Because this response is directed at internal, relatively conserved antigens, it affords some cross-protection within a
given subtype of inﬂuenza virus. With the possibility of a broader A(H1N1) Mexico outbreak in the fall of 2009, it appeared worthwhile
studying the degree of cellular immune response-mediated cross-reactivity among inﬂuenza virus isolates. The composition of the 2006–
2007 inﬂuenza vaccine included the A/New Caledonia/20/1999 strain (comprising a virus that has been circulating, and was included in
vaccine preparations, for 6–7 years) and two strains not previously included (Wisconsin and Malaysia). This combination afforded us the
opportunity to determine the degree of cross-reactive cellular immunity after exposure to new viral strains. We analysed the antibody
responses and the phenotype and function of the T cell response to vaccine components. The results obtained show that antibody
responses to A/New-Caledonia were already high and vaccination did not increase antibody or cytotoxic T lymphocyte responses.
These data suggest that repeated exposure to the same inﬂuenza stain results in limited boosting of humoral and cellular immune
responses.
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Introduction
Efﬁcacy of inﬂuenza vaccines has been correlated with a rise
in serum antibody titres, as long as the virus strain used in
the vaccine resembles the strain in circulation. After inﬂu-
enza vaccination, the humoral immune response requires
several days to effectively contain viral spread and eradicate
the virus. The immunologic memory established in this pri-
mary response results in long-lived resistance to re-infection
with homologous virus. Cross-protection within a subtype
of inﬂuenza has only rarely been observed and infections
induce essentially no protection across subtypes or between
types A and B [1,2]. Anti-haemagglutinin (HA) antibodies
protect against both disease and infection with homologous
virus. Serum HA-inhibiting titres of 1:40 or greater confer
protection against infection [3]. In recognition of these
deﬁned immune correlates, the induction of neutralizing anti-
bodies is one of the main goals of immunization.
CD8+ cytotoxic T lymphocytes (CTL) recognize epitopes
of HA or internal proteins M, NP, or PB2 presented in the
context of HLA class I molecules [2]. Depending on their anti-
gen speciﬁcity, CTLs may be subtype-speciﬁc; however, many
target relatively conserved, internal antigens and are thus
broadly cross-reactive among inﬂuenza A strains [4,5]. This
extensive cross-protection has attracted recent attention in
light of the swine-origin inﬂuenza A (H1N1) outbreak as well
as the fact that 60% of patients are under 18 years of age and
that questions exist about the degree of cross-protection
conferred by A (H1N1) and other inﬂuenza strains [6,7]
Cytokine responses may contribute to the elimination of
inﬂuenza-infected cells; however, it is considered that CD8+
effector T cells [8] eradicate infected cells mainly by CD95
(Fas)-mediated or perforin- and granzyme-mediated cytotox-
icity [9]. Intracellular cytokine staining proﬁles indicate that
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inﬂuenza epitope–speciﬁc CD8+ T cells are capable of
producing interferon (IFN)-c, often in combination with tumor
necrosis factor and occasionally interleukin (IL)-2 [10]. Mea-
sures of cellular immune response to inﬂuenza are correlated
with protection against inﬂuenza in the absence of strong
serum Ab responses among the elderly, and combining cellular
and humoral measures of vaccine efﬁcacy may increase the
ability to predict the risk of inﬂuenza illness [11,12]. Cross-
reactive T cell responses target relatively conserved internal
proteins and may confer some protection against novel
emerging strains. Lee et al. [13] demonstrated recognition of
multiple H5N1 peptides, predominantly from viral matrix and
nucleoprotein, by individuals residing in the UK who were not
likely exposed to H5N1 virus. The study suggests that regular
boosting of heterosubtypic CTLs may provide a broad protec-
tion against avian and human inﬂuenza [13,14].
After initial viral encounter, CD8+ memory T cells are
characterized by reduced requirements for co-stimulatory
signals in comparison to naı¨ve T cells and a quicker response
to antigenic restimulation [15–17]. The memory subsets are
differentiated based on surface expression of lymph node
homing chemokine receptor CCR7 and CD45RA. Phenotypi-
cally, cells co-expressing CCR7 and CD45RA are naı¨ve,
whereas CCR7+ CD45RA– are central memory and CCR7–
CD45RA– are effector memory. Because CTL responses are
directed toward relatively conserved epitopes, each re-expo-
sure in adults is a secondary response to some extent.
McElhaney et al. [18] compared single-dose and two-dose
inﬂuenza immunization in older adults and documented a
ten-fold decline in IL-10 levels after the ﬁrst dose. This
response persisted at least 16 weeks after vaccination. The
study revealed a correlation between the IFN-c:IL-10 ratio
and antibody titres in the single-dose group and a negative
correlation in the two-dose group. They concluded that a
Th1-mediated antibody response to the initial vaccination
and a Th2 response to the boosting, two-dose regimen
accounted for the difference and that only the Th1 response
elicited by single-dose vaccination would lead to effective
CTL cytokine production [18].
Inactivated inﬂuenza vaccine is the most common vaccine
used, with an efﬁcacy of 70–90% for preventing infection
with inﬂuenza virus, and with the correlate of protection
being a rise in serum antibody titre. Ohmit et al. [19]
documented a four-fold or greater antibody titre rise from
pre-vaccination levels among 66.7% of inactivated vaccine
recipients. Although these titres explain the protection affor-
ded by vaccine to young healthy adults, levels are typically
lower among elderly individuals with underlying medical
conditions as well as when the circulating viruses do not
match the strains included in the vaccine [20,21]. The
recommended 2006–2007 trivalent inﬂuenza vaccine virus
strains included A/New Caledonia/20/1999 (H1N1)-like, A/
Wisconsin/67/2005 (H3N2)-like and B/Malaysia/2506/2004-
like antigens [19]. One of these three strains, A/New Cale-
donia/20/1999, has been circulating and included in vaccine
preparations for the last 6–7 years (and thus is referred to
as ‘old’ strain in the text). This provides a unique opportu-
nity to study immune responses to a recurring inﬂuenza vac-
cine strain and to compare these with the responses to
novel ﬂu vaccine strains.
We conducted a study to determine antibody and CTL
response to the three vaccine strains in healthy adults. We
speciﬁcally sought to analyse the contribution of CD8+ T cell
memory subsets, referred to as central memory (TCM) and
effector memory (TEM), after inﬂuenza vaccination. We also
aimed to explore the role of immune exhaustion by repeated
vaccination with recurring vaccine components through com-
parison between the ‘old’ vaccine strain and the two ‘new
stains’ [A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/
2004] included in the vaccine preparation for the ﬁrst time
during the 2006–2007 season in Winnipeg, Canada.
Materials and Methods
Study groups
Study subjects included 14 healthy adult donors. The mean
age of participants was 37.5 years (range 23–60 years). Seven
of the volunteers had received inﬂuenza vaccine in preceding
years and seven had not. The volunteers attended a vaccina-
tion clinic at the University of Manitoba, Winnipeg, Canada.
All subjects provided their informed consent, and the study
was approved by the ethics review committee of the Univer-
sity of Manitoba. Participants were immunized with inacti-
vated trivalent inﬂuenza vaccine according to the Northern
Hemisphere recommendation for 2006–2007.
Blood for baseline and follow-up sampling was obtained
on days 7 and 30. Peripheral blood mononucleocytes
(PBMCs) were isolated from heparinized whole blood by
density gradient centrifugation using Ficoll-hypaque (Bio-Lynx,
Brockville, Canada) and washed twice in RPMI media (Sigma-
Aldrich, St Louis, MO, USA) containing 10% FBS (Gibco,
Carlsbad, CA, USA).
Clinical laboratory tests
Plasma was separated by centrifugation and stored at )80C.
Determination of antibody titres by a haemagglutination inhi-
bition assay (HIA) was performed at the National Inﬂuenza
Reference Laboratory, National Microbiology Laboratory,
Public Health Agency of Canada, Winnipeg.
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Phenotyping and functional ﬂow cytometry
Following PBMC isolation, cells were stained using a panel of
ﬂuorochrome-conjugated mAb including: CD4-AmCyan,
CD3-Alexa Fluor 700, CD8-Paciﬁc Blue, CD62L-PE, CCR7-
PE-Cy7, HLA DR-APC-Cy7 and CD38-APC (all from BD
Biosciences, San Diego, CA, USA) and CD45RA-ECD (Beck-
man Coulter, Fullerton, CA, USA). Cells were then washed
in Dulbecco’s phosphate-buffered saline (PBS) containing 2%
foetal calf serum (FCS) (Gibco) and resuspended in PBS.
One hundred thousand events per sample were acquired
using an LSRII ﬂow cytometer and analysis was performed
with FACSDiva software (BD Biosciences).
Following separation, PBMCs from each donor were incu-
bated in the presence of media (negative control), staphylo-
coccal enterotoxin B (SEB; Sigma), phytohaemagglutinin
(positive controls), and each of the three inﬂuenza vaccine
strains namely: A/New Caledonia/20/1999 (H1N1) (NC),
A/Wisconsin/67/2005 (H3N2) (WISC) and B/Malaysia/2506/
2004 (MAL). The antigens were added at a ﬁnal concentra-
tion of 10 haemagglutinin units/mL. The inﬂuenza strains
were obtained from the National Inﬂuenza Reference Labo-
ratory, Winnipeg, Canada. After 3 days of in vitro culture,
cells were incubated for a further 6 h in the presence of
GolgiPlug (BD Biosciences) to prevent secretion of cyto-
kines, followed by staining for ﬂow cytometric analysis.
After antigen stimulation, PBMCs were surface-stained
using a panel of ﬂuorochrome-conjugated mAb including:
CD4-AmCyan, CD3-Alexa Fluor 700, CD8-Paciﬁc Blue,
CD62L-PE, CCR7-PE-Cy7, HLA DR-APC-Cy7 (all from BD
Pharmingen, San Diego, CA, USA) and CD45RA-ECD (Beck-
man Coulter). Cells were then washed in Dulbecco’s PBS
containing 2% FCS (Gibco) and intracellular staining was per-
formed.
After surface staining, intracellular cytokine staining was
performed using the BD Cytoﬁx/Cytoperm Fixation/Permea-
bilization Kit according to manufacturer’s instructions (BD
Biosciences). Cytokines were detected using IFN-c-ﬂuorescein
isothiocyanate and IL-2-allophycocyanin (BD Biosciences).
One hundred thousand events per sample were acquired
using an LSRII ﬂow cytometer and analysis was performed
with FACSDiva software (BD Biosciences). The percentage
of cytokine-positive cells within the parent population was
determined and the stimulation index was calculated as the
ratio of cytokine-positive cells in stimulated vs. unstimulated
cultures.
Statistical analysis
Mean values (percent cells expressing a particular phenotype)
were compared between groups using the nonparametric
Mann–Whitney U-test; p £0.05 was considered statistically
signiﬁcant. The Kruskal–Wallis nonparametric test was used
for the calculation of trend between the three time points.
Results
Antibody titres
HIA was performed on all samples for each of the three vac-
cine components. Mean baseline titres were 52 (95% CI 95
0–130.7), 18.86 (95% CI 95 )6.45 to 31.26) and 4.857 (95%
CI 95 3.005–6.709) for New Caledonia/20/1999 (H1N1), A/
Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004,
respectively.
HIA titres on day 0 (before vaccination) and days 7 and
30 (after vaccination) for each of the strains contained in the
vaccine are shown in Fig. 1. Over this time period, HIA titres
for NC did not change, but statistically signiﬁcant increases
in antibody titres for WISC and MAL were noted (Kruskal–
Wallis p values for trend were: NC, 0.16; WISC, 0.0064 and
MAL, 0.0019).
Cellular immunity
Functional response to antigen-speciﬁc stimulation after vaccina-
tion. To determine the function of CD8+ T cells in response
to vaccine components, we stimulated freshly isolated PBMCs
with whole inﬂuenza viruses corresponding to the strains
included in the vaccine, at timepoints prior to vaccination, and
7 and 30 days after vaccination. After separate incubation with
each of the three vaccine strains, intracellular cytokine staining
was performed as previously described [22]. In vitro stimulation
with inﬂuenza virus was used to describe the cytokine produc-
tion in response to antigenic stimuli.
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FIG. 1. Haemagglutination inhibition assay titres for each of the vac-
cine components were determined for each study participants (New
Caledonia, Wisconsin, Malaysia) before vaccination (day 0) (check-
ered bar) and at two time points after vaccination (days 7 and 30)
(black and grey bars respectively); p values represent the trend
between three time points using Kruskal–Wallis analysis of variance.
NS, not signiﬁcant.
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Assessment of antigen-speciﬁc functional responses (IL-2
and IFN-c) is shown in Fig. 2. Brieﬂy, we gated on lympho-
cytes and, subsequently, on CD3+ and CD8+ cells. Within
the CD8+ cells, we gated on IFN-c and IL-2. This response
was compared with that of the same individual to NC (the
‘old’ vaccine component). We found increased IL-2 and IFN-
c production by CD8+ T-cells stimulated in vitro with WISC
compared to NC.
Phenotype and state of immune activation. Memory subset clas-
siﬁcation was performed by gating on CD8, and dividing the
CD8+ T cells into naı¨ve – CD8+ CD45RA+, central memory
(TCM) – CD8+ CD45RA) CCR7+ and effector memory
(TEM) cells – CD8+ CD45RA) CCR7).
Memory subsets were determined just before and 7 days
and 30 days after vaccination with inactivated inﬂuenza virus.
The distribution of memory subsets within the entire CD8
T-cell population did not change signiﬁcantly after vaccine
administration. This likely reﬂects that inﬂuenza-speciﬁc
responses represent a small portion of the total T cell repertoire.
Immune activation, as assessed by CD38 expression, was
measured for each of the three memory subsets (naı¨ve, TCM
and TEM). The proportions of activated CD8+ T cells were
determined and shown to be increased signiﬁcantly after
immunization with inactivated inﬂuenza virus in the naı¨ve
subpoulation only (Fig. 3).
Figure 4 depicts the data for all three vaccine strains
together. The IFN-c production by CD8+ TEM cells increased
signiﬁcantly after immunization, whereas the proportion of
CD8+ TCM cells that produce IFN-c showed a signiﬁcantly
decreased response. This likely represents the differentiation
of central memory T cells into effector and effector memory
cells.
Comparison of the functional response to ‘new’ vs. ‘old’ strains
after vaccination. To determine the function of inﬂuenza
CD8+ T cells to repeated vaccination, we compared the
IFN-c and IL-2 production in response to stimulation with
‘old’ and ‘new’ vaccine components, prior to and after vacci-
nation with trivalent inactivated vaccine.
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FIG. 2. Gating strategy. The gating strategy employed was to ﬁrst gate on lymphocytes (a) followed by CD3+ cells (b) and ﬁnally T cell subsets
(CD4 or CD8) (c). Then memory subsets, deﬁned by CD45RA and CCR7, were gated on (d). Functional responses on either T cell subsets
(CD4/CD8) or memory subsets (naı¨ve, TCM, TEM) were assessed by determining interleukin (IL)-2 and interferon (IFN)-c responses (e) using the
described intracellular staining protocol.
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Gated on IL-2 producing cells, the memory subset of
responding T cells was determined using expression of
CD45RA and CCR7. The IL-2 produced by TEM in response
to ‘new’ components increased signiﬁcantly after immuniza-
tion, whereas IL-2 produced by TCM decreased. Vaccination
did not signiﬁcantly alter the IL-2 production within either
subset in response to stimulation with the ‘old’ strain
(Fig. 5).
The same procedure was repeated for IFN-c. Gating on
IFN-c-producing cells, the memory subset of responding
T-cells was determined using expression of CD45RA and
CCR7. The IFN-c produced by TEM in response to ‘new’
components increased signiﬁcantly after immunization,
whereas no such increase was observed in response to the
‘old’ virus (Fig. 6).
Discussion
The inﬂuenza vaccine composition as recommended by the
WHO for 2006–2007 season in the Northern Hemi-
sphere presented an opportunity to assess the degree of
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FIG. 3. Total activation state within the CD8+ memory subsets. The activation state is expressed as the percentage of CD8+ T cells within the
population expressing the activation surface marker CD38; p values represent the trend between three time points using Kruskal–Wallis analysis
of variance. NS, not signiﬁcant.
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FIG. 4. Interferon (IFN)-c response
within the CD8+ memory subsets. The
responses pre- and post-vaccination to
all three vaccine components are plot-
ted together; p values represent the
trend between three time points using
Kruskal–Wallis analysis of variance.
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FIG. 5. Strain-speciﬁc interleukin (IL)-2 responses within memory subsets of ‘new’ strains (Wisconsin and Malaysia) compared to the ‘old’ strain
(New Caledonia). The responses are expressed as the percentage of CD8+ T cells of that memory class (either TEM or TCM); p values represent
the trend between three time points using Kruskal–Wallis analysis of variance. NS, not signiﬁcant.
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cross-reactive cellular immunity afforded by a circulating virus
that is present in vaccine formulations (NC) and to compare
it with that afforded by the ‘new’ components of the vaccine
(WISC and MAL). The present study was designed to care-
fully assess the the phenotype and function of T cell
responses to the ‘new’ and ‘old’ vaccine components, with
particular focus on the T cell memory compartments.
The antibody response measured using HIA showed
higher pre-immunization titres against the ‘old’ strain; how-
ever, the titre remained unchanged after vaccination. The
‘new’ strains started with lower HIA titres and then signiﬁ-
cantly increased after 7 and 30 days. The higher baseline
titre for the ‘old’ strain and lack of increase after vaccination
was observed even in the group that did not receive the vac-
cine in previous years, suggesting that the circulating virus
may have contributed to the already protective antibody at
the outset (data not presented).
Inﬂuenza-speciﬁc CD8+ T cells aid in the efﬁcient elimina-
tion of virus and in mediating subsequent host recovery.
These tasks are accomplished via the production of pro-
inﬂammatory cytokines and the direct killing of virus-infected
cells [4,5]. Some of the T cell responses to inﬂuenza virus
are directed at evolutionarily conserved sites within different
strains and are important for cross-strain reactivity, a notion
that provided the impetus for the present study. The cyto-
kine production within memory subsets, in response to
immunization, was studied using matching strains of whole-
virus as a T cell stimulus, and functional measurements
consisted of intracellular staining for IL-2 and IFN-c. The
proportion of CD8+ IFN-c+ lymphocytes within the effector
memory subset increased, whereas it decreased within the
central memory compartment. These reciprocal changes sug-
gest that, after vaccination, the TCM differentiate to become
IFN-c-producing effectors resulting in a decrease in central
memory cell frequency and an increase in the effector memory
cell type. Studying the reponse to speciﬁc epitopes using tet-
ramer staining is needed in the future for a better under-
standing of the clonal nature of the expanding TCM subset.
IL-2 and IFN-c production by CD8+ T-cells increased sig-
niﬁcantly 30 days after inﬂuenza vaccination in response to
‘new’ strains but not the ‘old’ strain (Figs 5 and 6). The IFN-
c response to the latter strain occurred earlier, peaking after
7 days, followed by a decrease on day 30. One possible
explanation for the decreased CD8+ T cell response to the
‘old’ inﬂuenza strain could be the presence of higher baseline
neutralizing antibody titres, attenuating the secondary T cell
response by limiting the antigen availability for presentation
to T cells. In the presence of less neutralizing antibody, more
antigen is available to induce an anamnestic T cell response.
This mechanism was shown to be operating in the case of
inﬂuenza infection [23,24]. These results are in contrast with
the well-demonstrated effect after exposure to a virus in
which the memory cell pool expands, leading to higher pre-
cursor frequency upon secondary exposure. The expansion
occurs at the expense of nonreacting memory T-cells [25].
A conceivable explanation for the discrepancy is that
repeated exposure to a circulating strain with its variants
leads to expansion of different clones directed at re-assorted
internal proteins, such that these replace pre-existing cells by
a process of attrition.Functional exhaustion of the CD8+
T cells has been reported mostly in chronic infections, char-
acterized by persistence of antigens such as hepatitis C virus
and HIV [26,27]. Repeated or high doses of antigen may be
associated with induction of tolerance or depletion of
responding CTLs. Using a vaccinia-virus epitope with variable
expression levels, Wherry et al. [28] demonstrated that the
highest expression was associated with a larger memory
pool; however, the function of these cells, as measured by
IFN-c, was diminished. Although it is not considered to be
important in acute transient viral infections, we speculate
that recurring exposure to NC circulating for several years
along with repeated vaccination could have led to dysfunc-
tional memory and hence the poor cytokine production by
CD8+ T cells observed in the present study.
The CD8+ T cell responses are considered to be impor-
tant with respect to protection from heterologous viruses
and, because they target preserved viral epitopes, they hold
promise for the prevention of potential epidemic strains of
inﬂuenza virus. These cross-reactive T cells can become acti-
vated and modulate the immune response and the outcome
of subsequent heterologous infections, and they have been
shown to expand at the cost of loss of noncross-reactive
clones [29,30].
Skewing of the CTL cytokine response toward a Th2 phe-
notype upon repeated vaccine administration [18] could
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FIG. 6. Strain-speciﬁc interferon (IFN)-c responses within memory
subsets, with ‘new’ strains (Wisconsin and Malaysia) compared to
the ‘old’ strain (New Caledonia). The responses are expressed as
the percentage of CD8+ T cells of that memory class (either TEM or
TCM); p values represent the trend between three time points using
Kruskal–Wallis analysis of variance. NS, not signiﬁcant.
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explain the lack of increase in IFN-c production observed
with NC. On the other hand, the absence of boosting of the
antibody response is in contrast to observations made by
McElhaney et al. [18].
The observation of decreased cellular response to
repeated administration of a component of the inﬂuenza vac-
cine, namely NC, compared to new strains is important. The
implications are that such re-vaccination with the same strain
may limit the development of a CD8 response and might
decrease the potential protection against heterologous inﬂu-
enza virus, which is considered to be mediated to a large
extent by these cells. The data also suggest that vaccination
with multiple inﬂuenza isolates is required to develop the
breadth in T cell response. The data may also be relevant
when considering potential vaccines against the H1N1 Mex-
ico inﬂuenza virus. Our data suggest that, although limited
cross-protective cellular immunity is offered by exposure to
other inﬂuenza strains, the maximal breadth and speciﬁcity
of T cell responses is only achievable with strain-speciﬁc
immunization. Studies that directly address the cross-protec-
tive immunity conferred by H1N1 Mexico and circulating
strains are needed.
The present study has demonstrated three notable points.
The ﬁrst is the observation of the evolution over time of a
memory subset of responding cells, documenting the conver-
sion of central memory T cells to a larger effector memory
compartment after vaccination. The second is the lack of
boosting of the antibody and CTL response by re-administra-
tion of a vaccine component that has been circulating and
included in the vaccine formulation for several years. The ﬁnal
point is that isolate-speciﬁc immunization is required for a
maximal breadth of T cell responses. This comprehensive
study of both antibodies and CD8+ T cells with comparison of
the three vaccine constituents provides information that may
be useful for future recommendations of vaccine formulations.
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